Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Novavax, Inc.NASDAQ: NVAX

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities falls 6.7% from a year ago

Other current liabilities stood at $132.45M at the end of Q1 FY2026, down 6.7% from a year earlier and down 44.0% from the prior quarter. Over 3 fiscal years it compounded at -37.8% a year.

Context

  • Other current liabilities amounted to 12.7% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
  • Other current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -6.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$132.45M-44.0% QoQ
Last fiscal yearDec 2025
$236.62M-15.5% YoY
Year agoMar 2025
$142.03M-6.7% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.7%——
1 year-15.5%——
3-year CAGR-37.8%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
236.62M USD
Year-over-year change
-15.5%
4-year CAGR
+33.5%

Other Current Liabilities vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -6.7% is the 4th highest of 8, against a peer median of -13.6%.
  • Other current liabilities amounts to 12.7% of total assets for NVAX, versus a peer median of 2.3%.
NVAX Competitors
Other Current Liabilities for NVAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€481.4M EUR+39.5%-28.8%2.4%
NVAXNovavax, Inc.Mar 2026$132.45M USD-6.7%-37.8%12.7%
MRNAModerna, Inc.Sep 2026$106M USD-88.1%+86.3%0.8%
VALNValneva SEMar 2026€50.99M EUR+68.8%-39.5%13.7%
EBSEmergent BioSolutions Inc.Mar 2026$30M USD-26.1%+16.4%2.3%
INOInovio Pharmaceuticals, Inc.Mar 2026$27.02M USD+70.3%+34.0%54.3%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$5.49M USD-13.6%+19.8%2.2%
PCVXVaxcyte, Inc.Jun 2026$0 USD-100.0%+347.5%0.0%
Peer median (excluding NVAX) —-13.6%+19.8%2.3%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.52B1.34B568.51M530.23M240.63M
Short-term Investments000392.89M494.45M
Net Receivables454.99M82.38M297.24M108.29M106.45M
Inventory8.87M36.68M41.7M8.75M11.55M
Other Current Assets56.11M86.68M166.15M32.51M125.2M
Total Current Assets2.16B1.7B1.14B1.13B978.28M
Property, Plant & Equipment (Net)228.7M400.49M490.99M300M67.7M
Goodwill131.48M126.33M127.45M107.48M113.46M
Intangible Assets4.77M0000
Long-term Investments1.65M1.66M000
Tax Assets(1.65M)(1.66M)000
Other Non-current Assets56.69M28.47M35.16M24M17.08M
Total Non-current Assets421.63M555.29M653.6M431.48M198.24M
Total Assets2.58B2.26B1.8B1.56B1.18B
Account Payables127.05M216.52M132.61M41.58M24.58M
Short-term Debt0324.88M000
Tax Payables00000
Deferred Revenue1.42B370.14M241.31M675.07M140.05M
Other Current Liabilities74.48M982.62M917.36M279.95M236.62M
Total Current Liabilities2.39B2.46B1.64B1.15B459.95M
Long-term Debt323.46M166.47M168.02M169.68M244.21M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)172.53M179.41M622.21M446.82M358.94M
Other Non-current Liabilities42.12M55.7M33.13M359.61M239.07M
Total Non-current Liabilities538.11M432.81M879.28M1.03B844.32M
Total Liabilities2.93B2.89B2.51B2.18B1.3B
Common Stock764K868K1.41M1.62M1.65M
Retained Earnings(3.62B)(4.28B)(4.82B)(5.01B)(4.57B)
Accumulated OCI(1.35M)(6.38M)2.72M(22.56M)2.01M
Other Stockholders Equity00000
Minority Interest00000
Total Equity(351.67M)(634.08M)(716.93M)(623.84M)(127.75M)
Total Debt453.99M549.78M229.08M230.42M248.81M
Net Debt(1.06B)(787.1M)(339.42M)(299.81M)8.18M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.